Skip to main content
Equibles
PACB logo

PACB

Pacific Biosciences Of California, Inc.
$1.53 +0.03 (+2.00%) At close · Jul 15
Market Cap
$479.88M
Shares
310,601,688

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.53 Open$1.51 Day$1.48–1.55 52W$1.09–2.73 Avg vol 30d5.9M Short int47.5M · 15.3% float · 6.5d Short vol44% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 8
Up next
Next earnings call
Aug 10, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 8, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 15.7 · calm Equity put/call 0.69
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −10%
      below
      Price vs 50-day avg +6%
      above
      RSI (14) 51
      neutral
      MACD trend Negative
      52-week position 27%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +16%
      trailing
      6-month return −37%
      trailing
      YTD return −18%
      this year
      Relative strength −47%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      7 of 229 funds reported for Jun 30 · net -302.3K sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      15.29% of float · ▼ -21.6% MoM · 6.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      229 holders — mid 3-yr range
      Squeeze score 76
      high risk · 0–100
      Fundamentals
      Weak
      Revenue growth +3%
      Y/Y
      Gross margin 49%
      expanding
      EPS growth −14%
      Y/Y
      Free cash flow $-113.9M
      Balance sheet $833.0M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 88%
      annualized · 1-yr
      Max drawdown −57%
      past year
      ATR 7.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record
      Latest guidance · from the 8-K filed May 7, 2026
      Revenue · full year 2026 Lowered $165M – $175M
      prior FY $160.01M midpoint +6.2% Y/Y

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −10% Bearish
      Price vs 50-day avg
      +6% Bullish
      RSI (14)
      51 Neutral
      MACD trend
      Negative Bearish
      52-week position
      27% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      7 of 229 funds reported for Jun 30 · net -302.3K sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      15.29% of float · ▼ -21.6% MoM · 6.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      229 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $1 Now $2 · 27% 52-wk high $3
      vs 200-day avg -10% vs 50-day avg +6%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Non-GAAP net loss non-GAAP $35.9M Q1 2026 —
      Non-GAAP net loss per share non-GAAP $0.12 Q1 2026 —
      Non-GAAP operating expenses non-GAAP $49.9M Q1 2026 —
      cumulative Revio shipments 346 end of Q1 2026 call —
      cumulative Vega shipments 174 end of Q1 2026 call —
      Revio systems shipped 15 first quarter 2026 call —
      Vega systems shipped 27 first quarter 2026 call —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PACB
      Pacific Biosciences Of California, Inc.
      this stock
      		$479.88M -18.2% +3.0% — 15.3%
      ABT
      Abbott Laboratories
      		 $154.67B -28.4% +5.7% 24.9 1.3%
      SYK
      Stryker Corp
      		 $120.24B -9.7% +11.2% 36.3 1.8%
      MDT
      Medtronic plc
      		 $102.89B -15.5% +8.4% 21.6 1.5%
      BSX
      Boston Scientific Corp
      		 $64.07B -54.9% +5.5% 18.0 1.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      228
      % held
      60.0%
      Reported
      7 of 229
      Top holder
      ARK Investment Management…
      Held Float
      View
      Held by Funds
      Fund positions
      132
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      47.5M
      Days to cover
      6.5d
      Change
      -13.1M sh
      View
      Short Volume
      Short vol %
      44%
      As of
      Jul 15, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      493.4K
      Value
      $853.5K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      51.2%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $78.6M
      Net income (FY)
      $-546.4M
      EPS diluted
      $-1.82
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 9, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $120.8K
      Shares
      88.2K
      Filed
      Apr 1, 2026
      View
      Exempt Offerings
      Offering
      $84.8M
      Filed
      Oct 19, 2023
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 15, 2026
      Last call
      May 7, 2026
      View
      Investor Relations
      Upcoming events
      17
      View

      Performance

      5D 20D 120D MTD YTD
      PACB +2.0% +15.9% -36.8% -8.9% -18.2%
      SPY +1.3% -0.2% +10.1% +1.1% +10.7%
      vs SPY +0.7% +16.1% -46.9% -10.0% -28.9%
      Key facts CIK 1299130 CUSIP 69404D108 13F (30d) 6 filings 6 filers Visit website

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)